BioCryst Pharma (BCRX) Misses Q4 EPS by 23c
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.78 --0%
EPS Growth %: -43.8%
Financial Fact:
Product sales: 0
Today's EPS Names:
OCCI, ALZN, ASPU, More
EPS Growth %: -43.8%
Financial Fact:
Product sales: 0
Today's EPS Names:
OCCI, ALZN, ASPU, More
Join SI Premium – FREE
BioCryst Pharma (NASDAQ: BCRX) reported Q4 EPS of ($0.40), $0.23 worse than the analyst estimate of ($0.17). Revenue for the quarter came in at $79.5 million versus the consensus estimate of $75.57 million.
For earnings history and earnings-related data on BioCryst Pharma (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Royal Caribbean to acquire 50% stake in Sandals Resorts for $3 billion
- UBS Upgrades Bajaj Finance Ltd. (BAF:IN) to Neutral
- Aytu BioScience (AYTU) Tops Q4 EPS by 28c
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
